City of Hope Selects TrialMaster to support clinical trials
OmniComm Systems, Inc. to deploy
a Technology Transfer of the TrialMaster® electronic data
capture (EDC) solution for clinical data collection
FT. LAUDERDALE, FL – July 11, 2007 – /MarketWire/ - OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), one of the fastest growing companies in the Electronic Data Capture (EDC) marketplace, today announced that City of Hope has selected OmniComm’s EDC solution, TrialMaster and has entered into negotiations on the contract to support its clinical trials, including Principal Investigator initiated and federally funded trials. City of Hope also plans to utilize the OmniComm solution to provide EDC capabilities for the California Cancer Consortium which is comprised of City of Hope, UC Davis Cancer Center, University of Southern California/Norris Comprehensive Cancer Center, University of Pittsburgh Cancer Institute and affiliated sites. OmniComm also announced that it will work with City of Hope to establish an annual Users Group meeting to be held at the City of Hope campus in Duarte, California.
“OmniComm is truly honored to be chosen as the first line EDC solution by City of Hope,” said Cornelis F. Wit, CEO of OmniComm. “Our consulting services team looks forward to delivering superior support and training services to City of Hope as they transition to bring TrialMaster in-house.”
“Our extensive experience in conducting oncology trials has uniquely positioned us to be able to provide the solutions and support that are specific to the operational environment of the cancer centers,” said Stephen Johnson, Sr. VP of Business Development at OmniComm. “We are looking forward to working in tandem with City of Hope to develop a library of National Cancer Institute (NCI)-elated reusable electronic case report forms (eCRFs) and to developing product enhancements that will support the full technology transfer of TrialMaster to City of Hope.”
At any given time, City of Hope conducts more than 300 clinical trials encompassing prevention, screening, treatment, symptom management and quality of life.
Joyce Niland, Ph.D., the Edward and Estelle Alexander Chair in
Information Sciences and Associate Director for Information
Sciences at City of Hope Cancer Center, states, “As an
NCI-designated Comprehensive Cancer Center, with a long history of
leading edge research and biomedical informatics development,
adopting the OmniComm product has great potential to further
enhance City of Hope’s clinical trials enterprise. We are
excited to work with OmniComm to integrate emerging national and
international standards into this product, such as the CDISC
Protocol Representation, the BRIDG information model, and the NCI
caBIG modules. We look forward to hosting an interactive and
productive OmniComm User Group on our campus over the coming
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm’s growing base of satisfied customers is a direct result of the company’s commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm’s client intuitive pricing model allows companies that range from small to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments.
OmniComm ranked in the top 150 as one of the fastest revenue growth technology companies in North America during the last 5 years. In a market overview titled “The Promise of Next-Gen eClinical Trial Software” by Forrester Research, OmniComm was given the highest rating among its competitors for industry middleware. OmniComm Systems Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Germany, California, Maryland, New York, North Carolina and Texas.
Safe Harbor Disclaimer
Statements about OmniComm’s future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm’s operations, markets and profitability, actual results could differ materially and adversely from the expected results.
OmniComm Systems, Inc.
954-473-1254 Extension 283
Posted: July 2007